2 Pharma Stocks That Could Benefit From Faster Drug Approvals and Growing Oncology Opportunities
India, Nov. 17 -- The Indian pharmaceuticals industry may be entering a stage where fast approvals and innovation can become significant catalysts for its growth. For multinationals operating in the pharmaceutical industry, fast approval times could help minimize the difference in the launch time of a new drug across various regions. These could be particularly beneficial for those companies which have specialized portfolios in oncology, vaccines and advanced treatments.
Some of the companies that could see a positive effect due to these factors include GSK Pharmaceuticals and Pfizer India. The research firm Bernstein has kept a rating of 'Outperform' on both of these stocks.
Regulatory Reforms Could Improve the Pace of Drug Launches
T...
Click here to read full article from source
इस लेख के रीप्रिंट को खरीदने या इस प्रकाशन का पूरा फ़ीड प्राप्त करने के लिए, कृपया
हमे संपर्क करें.